Stock fact sheet · data as of
Lifecore Biomedical, Inc. (LFCR): fair value, margin of safety and Wheel Score
Ticker symbol LFCR · Healthcare · Drug Manufacturers - Specialty & Generic · United States · Speculative
Is LFCR undervalued?
LFCR closed at 6.44 on 5 Nov 2026, more than 30% above the GLS average fair value of 0.9450. Only 0 of the 1 models that produced a value sit above the price. By our models the shares are priced well beyond what the filed earnings, cash flow and book value support; the "below fair value" Wheel Trade Filter keeps names like this under 70.
The average is built from just 1 models (10 Cap) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
The nightly engine files LFCR under Speculative - it is losing money or its Piotroski health score is 3 or lower - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for LFCR
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | 0.9450 | -85% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -4.33 | -167% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 6.39 | -1% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Lifecore Biomedical, Inc. scores 5 of 9 on the Piotroski F-score: a middling result that falls one point short of the "Piotroski 6 or more" Wheel Trade Filter. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. A GLS Moat score of 0.7/10 is a weak reading: the accounts do not show returns and margins that competitors have been unable to wear down, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -24.0%, ROE 216.8%, ROA -13.3% - with debt at -10.04 times equity and a free-cash-flow yield of 0.3%.
Lifecore Biomedical, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 9/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 5 / 9 | ROIC | -24.0% |
|---|---|---|---|
| GLS Moat | 0.7 / 10 | ROE | 216.8% |
| Debt / equity | -10.04 | ROA | -13.3% |
| Free-cash-flow yield | 0.3% | Payout ratio | 0% |
| Institutions | 9 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 10: Weak
With a Wheel Score of 10 Lifecore Biomedical, Inc. sits in the Weak band. It fails filter 1, options that actually trade - options too quiet (4,007 open interest, 85 a day); and filter 2, a real business, not a gamble - speculative (a loss, or a weak Piotroski score); and filter 3, below fair value - trades 581% above our fair value; and filter 4, financially healthy - Piotroski 5/9 (under 6); and filter 5, can repay its debt - 10.8 years to repay its debt (over 3); and filter 6, no serious red flags - Red Flags score 40 (under 60); and filter 7, a premium worth selling - implied volatility 145% (over 80%); and filter 8, big enough - market cap $244M (under $1.0B); Value (weak) is its weakest part.
Implied volatility is 145%, above the 80% ceiling of the Wheel Trade Filter on premium. The premium looks generous, but moves of that size can blow through any strike. Chain open interest is 4,007 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 271k shares a day on a market cap of $244M, with a beta of 0.99; the Stability part of the Wheel Score rates that fair.
| Filter | Wheel Trade Filter | Result | Detail |
|---|---|---|---|
| 1 | Options that actually trade | Fails | options too quiet (4,007 open interest, 85 a day) |
| 2 | A real business, not a gamble | Fails | speculative (a loss, or a weak Piotroski score) |
| 3 | Below fair value | Fails | trades 581% above our fair value |
| 4 | Financially healthy | Fails | Piotroski 5/9 (under 6) |
| 5 | Can repay its debt | Fails | 10.8 years to repay its debt (over 3) |
| 6 | No serious red flags | Fails | Red Flags score 40 (under 60) |
| 7 | A premium worth selling | Fails | implied volatility 145% (over 80%) |
| 8 | Big enough | Fails | market cap $244M (under $1.0B) |
| 9 | Not a penny stock | Passes | Share price $5 or more |
| How it ranks | Rating | From | |
|---|---|---|---|
| Value | Weak | 581% above fair value | |
| Premium | Weak | implied volatility 145% | |
| Moat | Weak | moat 0.7/10 | |
| Health | Fair | Piotroski 5/9 | |
| Red Flags | Weak | Red Flags score 40/100 | |
| Option trading | Weak | 85 contracts a day, 4,007 open interest | |
| Stability | Fair | beta 0.99, $244M company |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls: a stock must pass all 9 Wheel Trade Filters to score 70, and the score then ranks the ones that pass; the Sunday Scan is the top 10. It is updated nightly and is not a recommendation. How the Wheel Score works · the walkthrough lesson shows how it fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for LFCR in the nightly calendar.
No analyst upgrades or downgrades were recorded in the last 30 days.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Lifecore Biomedical, Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| ELTP Elite Pharmaceuticals, Inc. | 0.2400 | 6.18 | +96% | 33No options | $259M |
| GLAS Glass House Brands Inc | 2.58 | 54.75 | +95% | 30Weak | $227M |
| SIGA SIGA Technologies, Inc. | 3.15 | 8.74 | +64% | 35Weak | $226M |
| EBS Emergent BioSolutions Inc. | 5.90 | 45.07 | +87% | 36Weak | $303M |
| CGC Canopy Growth Corporation | 0.7517 | - | - | 11Weak | $318M |
| TLRY Tilray Brands, Inc. | 2.96 | - | - | 24Weak | $331M |
| ACB Aurora Cannabis Inc. | 5.24 | - | - | 27Weak | $332M |
| NIKA Nika Pharmaceuticals Inc. | 0.3500 | 0.0000 | -19409229% | 11No options | $367M |
| VRNO Verano Holdings Corp | 5.16 | 27.65 | +81% | 30No options | $376M |
| KMDA Kamada Ltd. | 7.42 | 14.28 | +48% | 33Weak | $428M |
| OGI Organigram Global Inc. | 0.9650 | 11.09 | +91% | 30Weak | $136M |
| DERM Journey Medical Corporation | 4.73 | - | - | 23Weak | $134M |
Scan the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the top 10 stocks that pass all 9 Wheel Trade Filters, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about LFCR
Is LFCR undervalued right now?
No: at 6.44 the stock trades 581% above the GLS average fair value of 0.9450 (data as of 5 Nov 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of LFCR and what does it mean?
LFCR scores 10 out of 100 (Weak) - it fails Wheel Trade Filters 1, 2, 3, 4, 5, 6, 7, 8. The Wheel Score ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned - in two parts: the 9 pass/fail Wheel Trade Filters (busy options, a real business, below fair value, Piotroski 6 or more, debt it can repay, a Red Flags score of 60 or more, implied volatility of 25-80%, a $1 billion company, $5 a share) and a ranking of how strongly a stock passes on value, premium, moat, health, red flags, option trading and stability. A stock that fails any filter stays under 70; 70-84 is Good, 85 and above is Prime. The Sunday Scan is the top 10 that pass, sorted by Wheel Score.
What is the GLS fair value for LFCR?
0.9450 per share as of 5 Nov 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Lifecore Biomedical, Inc. report earnings next?
No upcoming earnings date is recorded for LFCR in our calendar as of 5 Nov 2026; the Calendars page is refreshed every morning.
Does LFCR have listed options, and how liquid are they?
Yes. The nightly snapshot found 8 listed contracts with 4,007 open interest across all expiries and implied volatility of 145% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.